The N-Terminal Part of the 1A Domain of Desmin Is a Hot Spot Region for Putative Pathogenic DES Mutations Affecting Filament Assembly.
Andreas BrodehlStephanie HollerJan GummertAndreas BrodehlPublished in: Cells (2022)
Desmin is the major intermediate filament protein of all three muscle cell types, and connects different cell organelles and multi-protein complexes such as the cardiac desmosomes. Several pathogenic mutations in the DES gene cause different skeletal and cardiac myopathies. However, the significance of the majority of DES missense variants is currently unknown, since functional data are lacking. To determine whether desmin missense mutations within the highly conserved 1A coil domain cause a filament assembly defect, we generated a set of variants with unknown significance and systematically analyzed the filament assembly using confocal microscopy in transfected SW-13, H9c2 cells and cardiomyocytes derived from induced pluripotent stem cells. We found that mutations in the N-terminal part of the 1A coil domain affect filament assembly, leading to cytoplasmic desmin aggregation. In contrast, mutant desmin in the C-terminal part of the 1A coil domain forms filamentous structures comparable to wild-type desmin. Our findings suggest that the N-terminal part of the 1A coil domain is a hot spot for pathogenic desmin mutations, which affect desmin filament assembly. This study may have relevance for the genetic counselling of patients carrying variants in the 1A coil domain of the DES gene.
Keyphrases
- copy number
- wild type
- genome wide
- single cell
- left ventricular
- cell therapy
- induced pluripotent stem cells
- newly diagnosed
- magnetic resonance
- induced apoptosis
- prognostic factors
- heart failure
- dna methylation
- computed tomography
- transcription factor
- gene expression
- magnetic resonance imaging
- intellectual disability
- big data
- skeletal muscle
- cell death
- mesenchymal stem cells
- amino acid
- cell cycle arrest
- bone marrow
- deep learning
- genome wide identification
- antiretroviral therapy
- artificial intelligence
- high glucose